CRISPR Therapeutics AG (CRSP) is a publicly traded Healthcare sector company. As of October 3, 2026, CRSP trades at $55.36 with a market cap of $5.36B and a P/E ratio of -11.56. CRSP moved -0.09% today. Year to date, CRSP is +3.09%; over the trailing twelve months it is -23.88%. Its 52-week range spans $30.04 to $78.48. Analyst consensus is buy with an average price target of $73.58. Rallies surfaces CRSP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
13 analysts cover CRSP: 0 strong buy, 8 buy, 5 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $73.58.
| Metric | Value |
|---|---|
| Price | $55.36 |
| Market Cap | $5.36B |
| P/E Ratio | -11.56 |
| EPS | $-4.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $78.48 |
| 52-Week Low | $30.04 |
| Volume | 947.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $13.39M |
| Net Income | $-451.14M |
| Gross Margin | 0.00% |
13 analysts cover CRSP: 0 strong buy, 8 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $73.58.